
Please try another search
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple-negative breast cancer; ABV-1504, which has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. ABVC BioPharma, Inc. is headquartered in Fremont, California, and operates as a subsidiary of YuanGene Corporation.
Name | Age | Since | Title |
---|---|---|---|
Tsang Ming Jiang | 65 | 2017 | Director |
Yen-Hsin Chou | 37 | 2017 | Independent Director |
Chang-Jen Jiang | 69 | 2017 | Director |
Norimi Sakamoto | 55 | 2017 | Independent Director |
Tsung-Shann Jiang | 71 | 2019 | Chief Scientific Officer, Chief Strategy Officer & Director |
Eugene Jiang | 39 | 2015 | Chairman & Chief Business Officer |
Susanna Cunningham-Rundles | - | - | Member of Scientific Advisory Board |
Che-Wei Hsu | 44 | 2022 | Independent Director |
Thomas P. Laughren | - | 2023 | Member of Scientific Advisory Board |
Shuling Jiang | 69 | 2022 | Director |
Yoshinobu Odaira | 76 | 2019 | Independent Director |
Yih-Shiou Hwang | - | 2023 | Member of Scientific Advisory Board |
Yu-Min Chung | 60 | 2022 | Independent Director |
Maurizio Fava | - | 2023 | Member of Scientific Advisory Board |
Hsin-Hui Miao | 59 | 2022 | Independent Director |
Keith McBurnett | - | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review